A single-dose LSD pill from Definium cut anxiety in a 214-person Phase 3 trial

A single dose of pharmaceutical-grade LSD, swallowed under medical supervision, cut generalized anxiety symptoms in a 214-person, placebo-controlled Phase 3 trial reported on Wednesday by Definium Therapeutics. The win is the company's second pivotal Phase 3 result in two months and lands on a drug the FDA has tagged a "breakthrough therapy," a designation reserved for medicines that could meaningfully improve on existing care.

That result, more than the molecule itself, is what makes the readout worth a second look. Modern psychiatric dosing is built around the daily pill. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), the standard first-line drugs for generalized anxiety disorder, take four to six weeks to reach full effect and leave a large share of patients without adequate relief. Benzodiazepines work within hours but carry dependence risks that limit long-term use. A monitored, single-dose treatment that produces a clinically meaningful reduction on a standard anxiety scale is a different unit of care, and that unit is the news.

Definium reported the top-line Phase 3 result on Wednesday, filing an 8-K with the Securities and Exchange Commission that attaches a corporate "Voyage" presentation and a press release. The drug, DT120, is a single dose of lysergide D-tartrate, pharmaceutical-grade LSD, formulated as an orally disintegrating tablet using Catalent's Zydis fast-dissolve technology. The STAT+ pickup framed the result as the first of two pivotal Phase 3 trials Definium is running in generalized anxiety disorder. The company has not yet disclosed the trial's primary endpoint name, effect size, or p-value in publicly available materials, and Definium's pipeline page lists the readout only as a top-line success.

The "breakthrough" designation follows a regulatory process that requires early evidence of substantial improvement over existing treatments. Definium's ODT formulation is covered by issued US patent 12,036,220, originally filed by the company when it was still Mind Medicine (MindMed), and a newer method-of-manufacture patent published in January 2026 covering lyophilized orally disintegrating tablets at 0.01 to 1 milligram doses. The company rebranded from MindMed to Definium Therapeutics earlier in 2026, so the DT120 program is a continuation of what was previously known as MM120.

Trade press coverage and investor news picked up the announcement after Definium's 8-K. Generalized anxiety disorder is one of the most common psychiatric conditions in the United States, with multiple national surveys putting lifetime prevalence in the teens to low-twenties percent range. Standard-of-care medications have not changed materially in two decades. The clinical-trial result says nothing yet about how long a single dose's effect lasts, whether the benefit survives repeat episodes, or how the drug compares head-to-head against optimized SSRI or SNRI therapy, all questions a second pivotal trial would have to address before Definium can file for approval.

Definium's second pivotal GAD trial has not yet read out. The company's own pipeline page lists DT120 as a candidate for both generalized anxiety disorder and major depressive disorder. Definium's previous Phase 3 win, in major depressive disorder, was reported roughly two months before Wednesday's anxiety readout. Two consecutive pivotal successes would move the program toward a regulatory filing. One pivotal win, plus a still-blank slate on durability data, keeps the story at the top-line-success stage the company has so far disclosed.